- Home
- NIE vs PRTA Comparison
NIE vs PRTA Comparison
Compare NIE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NIE | PRTA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.5M | 595.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NIE | PRTA |
|---|---|---|
| Price | $24.96 | $10.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 70.5K | ★ 600.6K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $819.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.61 | $4.32 |
| 52 Week High | $22.47 | $17.66 |
Technical Indicators
Market Signals| Indicator | NIE | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 49.53 |
| Support Level | $25.43 | $9.69 |
| Resistance Level | $25.75 | $10.50 |
| Average True Range (ATR) | 0.26 | 0.56 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 24.27 | 36.44 |
Price Performance
Historical ComparisonAbout NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.